- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Lupin and YL Biologics Receive Japanese Approval for Etanercept Biosimilar
Lupin and YL Biologics announced today that they have received approval to manufacture and sell YLB113, a biosimilar etanercept product, in Japan. The product will be Lupin’s first biosimilar to come to the Japanese market.
Lupin and YL Biologics announced today that they have received approval to manufacture and sell YLB113, a biosimilar etanercept product, in Japan. The product will be Lupin’s first biosimilar to come to the Japanese market.
Cyrus Karkaria, PhD, president of Lupin, said in a statement that “the successful filing and eventual approval of YLB113 is a major step in the fight against [autoimmune] diseases, and will allow access to an effective, affordable equivalent. After significant investment in our biotechnology [research and development] division over the years, this is the first biosimilar for regulated markets developed in-house at Lupin and the first etanercept biosimilar developed by an Indian pharmaceutical player. It is an important achievement for us that sets the tone for future biosimilar development.”
Lupin submitted its application for the etanercept biosimilar to Japanese authorities in 2018 for all indications of the reference product. The application included data from a global phase 3 clinical trial of the drug, in comparison with the reference Enbrel, conducted at 110 centers in 11 countries.
The study’s primary endpoint was equivalent improvement in rheumatoid arthritis, measured by American College of Rheumatology (ACR) criteria for 20% improvement (ACR20), at week 24. YL Biologics reported in February 2018 that the proportion of patients achieving ACR20 fell within a prespecified equivalence margin used by most advanced regulatory agencies in granting marketing authorizations. The safety and immunogenicity of YLB113 were also similar to those of the reference Enbrel.
In addition to Japan, Lupin is targeting other major regulatory territories with its biosimilar etanercept; the drug maker announced in May 2018 that it has submitted a marketing authorization application for the biosimilar to the European Medicines Agency. In 2018, Lupin said that it would submit the biosimilar for US regulatory approval in the third quarter of 2020.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
